Figure 1From: Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer’s disease clinical trials Time to discontinuation models. In time to early discontinuation models for each study program arm, Japan differed significantly from South America/Mexico in the IDENTITY active semagacestat arms (A), from Asia and Eastern Europe/Russia in the IDENTITY placebo arms (B), from North America in the EXPEDITION active solanezumab treatment arms (C), and from Eastern Europe/Russia for the EXPEDITION placebo arms (D) (P < 0.01 for all comparisons by log-rank test). Eastern Europe/Russia differed from Australia/South Africa, North America, and Western Europe/Israel in the IDENTITY placebo arms (P < 0.01 by log-rank test). South America/Mexico differed from Western Europe/Israel in the IDENTITY active semagacestat arms (P < 0.01 by log-rank test).Back to article page